Is BioNTech (BNTX) a Great Value Stock Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One stock to keep an eye on is BioNTech (BNTX). BNTX is currently sporting a Zacks Rank of #2 (Buy) and an A for Value.
Investors should also recognize that BNTX has a P/B ratio of 2.17. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. BNTX's current P/B looks attractive when compared to its industry's average P/B of 3.18. Over the past year, BNTX's P/B has been as high as 16.35 and as low as 1.70, with a median of 3.01.
Finally, investors should note that BNTX has a P/CF ratio of 2.75. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 7.14. BNTX's P/CF has been as high as 23.37 and as low as 2.12, with a median of 3.70, all within the past year.
iTeos Therapeutics (ITOS) may be another strong Medical - Biomedical and Genetics stock to add to your shortlist. ITOS is a # 2 (Buy) stock with a Value grade of A.
iTeos Therapeutics also has a P/B ratio of 1.44 compared to its industry's price-to-book ratio of 3.18. Over the past year, its P/B ratio has been as high as 4.53, as low as 0.94, with a median of 2.36.
These are just a handful of the figures considered in BioNTech and iTeos Therapeutics's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that BNTX and ITOS is an impressive value stock right now.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report
iTeos Therapeutics, Inc. (ITOS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
